Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Eur J Dermatol. 2022 Apr 1;32(2):181-186. doi: 10.1684/ejd.2022.4241.
Sebaceous carcinoma and sweat gland carcinoma (malignant tumours with apocrine and eccrine differentiation) are rare malignant adnexal tumours that differentiate toward sebaceous glands and eccrine and apocrine glands, respectively. Because of the rarity of these malignancies, standard treatments for advanced disease have yet to be established. The outcomes of patients with systemic metastasis remain poor, highlighting the need for novel treatment strategies. Nectin cell adhesion molecule 4 (NECTIN4) and its antibody-drug conjugate, enfortumab vedotin, have attracted attention as potential treatments for solid tumours.
To examine the potential use of NECTIN4-target therapy for sebaceous and sweat gland carcinoma.
MATERIALS & METHODS: We immunohistochemically investigated NECTIN4 expression in 14 sebaceous carcinoma samples and 18 sweat gland carcinoma samples, and examined whether NECTIN4-targeted therapy could be applied to these cancers.
We found strong and frequent expression of NECTIN4 in both cancers. All tumours exhibited positive staining at least in a part of the lesion, and the mean H-score, a semiquantitative score ranging from 0 to 300, was 259.4 for sebaceous carcinoma and 253.1 for sweat gland carcinoma.
Our results suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with NECTIN4-targeted antibody-drug conjugates, such as enfortumab vedotin.
皮脂腺癌和汗腺癌（具有顶泌汗腺和外泌汗腺分化的恶性肿瘤）是罕见的恶性附属器肿瘤，分别向皮脂腺和外泌汗腺及顶泌汗腺分化。由于这些恶性肿瘤较为罕见，尚未确定晚期疾病的标准治疗方法。发生全身转移的患者预后较差，这突出表明需要新的治疗策略。 nectin 细胞黏附分子 4（NECTIN4）及其抗体药物偶联物恩特妥珠单抗已被认为是治疗实体瘤的潜在药物。
研究 nectin4 靶向治疗在皮脂腺癌和汗腺癌中的潜在应用。
我们采用免疫组织化学方法检测了 14 例皮脂腺癌样本和 18 例汗腺癌样本中 NECTIN4 的表达情况，并探讨了 nectin4 靶向治疗是否可应用于这些癌症。
我们发现两种癌症均存在 NECTIN4 的强阳性和高频表达。所有肿瘤在病变的至少一部分均呈阳性染色，NECTIN4 的平均 H 评分（范围为 0 至 300 的半定量评分）为 259.4（皮脂腺癌）和 253.1（汗腺癌）。
我们的结果表明，皮脂腺癌和汗腺癌都可能可以通过 nectin4 靶向抗体药物偶联物（如恩特妥珠单抗）进行治疗。
